- The PDUFA date for the FDA's review of Zogenix's (ZGNX -3.9%) supplemental New Drug Application (sNDA) for an abuse deterrent formulation of Zohydro ER is this Friday, January 30. If approved, the company will transition to the new product by Q2.
- Previously: Zogenix submits sNDA for abuse deterrent Zohydro (Oct. 1, 2014)